Print
The American Society of Clinical Oncology’s ASCO 2013 Annual Meeting kicks off in Chicago May 31. Though the meeting attracts cancer researchers and physicians from around the world, it is closely watched by Wall Street for news of clinical trial results that could send stocks soaring or sinking. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about a new class of cancer therapies likely to get big attention at this year’s meeting, what other news will be coming out of the conference, and whether concerns about payers willingness to continue meeting the high price commanded by new cancer therapies becomes a topic of discussion in Chicago. Read More
Partnering
GSK and BARDA Collaborate to Develop New Antibiotics The $200M deal seeks to create a pipeline of new drugs. Read More.Trials and Tribulations
Pfizer Drug Fails Three Late-stage TrialsThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Dealmaking
AbbVie Options Alvine Celiac Drug for $70 MillionCollaboration could broaden pharma’s autoimmune pipeline. Read More.Business Strategy
Astellas to Consolidate R&D Japanese pharma plans to outsource some functions while bringing others closer to its headquarters. Read More.Trials and Tribulations
Drug Recalls Up Over Last YearThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Business Strategy
Already an Internet Favorite, Pfizer Takes Viagra Sales OnlineMove intended to combat sites that peddle counterfeit versions of the drug. Read More.Trials and Tribulations
Lilly’s Late-Stage Lymphoma Drug Fails The weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Drug Sales
Patent Expirations Help Cut Drug Spending in 2012The 3.5 percent decline is first drop ever. Read More.Drug Development
Baxter Alzheimer’s Late-Stage Candidate FailsCompany will complete analysis of data, but won’t continue development. Read More.Dealmaking
Celgene Strikes A Deal with ConcertBig Biotech’s $300 million tie up with Concert Pharmaceuticals is the fourth such deal in past two months. Read More.Interview
Why Gene Therapy Is Coming of AgePodcast: May 6, 2013 Read More.Trials and Tribulations
Aveo and Astellas Trial Fails to Impress Advisory PanelThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Drug Development
Merck and Pfizer Collaborate on Diabetes DrugGlobal agreement ties partners together in march toward late-stage trials. Read More.Dealmaking
AstraZeneca Makes a String of Early-Stage DealsPatent losses took a toll on the company’s first quarter earnings. Read More.Trials and Tribulations
Novartis Faces Federal Claims of Kickbacks in Civil CourtThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.
.gif)
.png){kind=small} |
 |